新旧抗肥胖药物。
Old and new anti-obesity drugs.
作者信息
Dodangeh Salimeh, Hasani-Ranjbar Shirin
机构信息
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
出版信息
J Diabetes Metab Disord. 2024 Dec 19;24(1):16. doi: 10.1007/s40200-024-01512-5. eCollection 2025 Jun.
Abstract
Obesity is a pandemic problem that correlates with a cluster of metabolic factors leading to poor cardiovascular outcomes, morbidity, and an increased risk of overall mortality. It is necessary to approach obesity with a comprehensive treatment plan, which may involve lifestyle modifications (diet, exercise, and behavioral therapy) and pharmacological interventions. This article provides an overview of the mechanisms of action, efficacy, and safety of available long-term anti-obesity drugs and introduces other potential agents under investigation.
摘要
肥胖是一个全球性的问题，它与一系列代谢因素相关，这些因素会导致不良的心血管结局、发病率以及总体死亡风险增加。采用全面的治疗方案来应对肥胖是必要的，这可能包括生活方式的改变（饮食、运动和行为疗法）以及药物干预。本文概述了现有长期抗肥胖药物的作用机制、疗效和安全性，并介绍了其他正在研究的潜在药物。
相似文献
1
Old and new anti-obesity drugs.新旧抗肥胖药物。
J Diabetes Metab Disord. 2024 Dec 19;24(1):16. doi: 10.1007/s40200-024-01512-5. eCollection 2025 Jun.
2
Comparative efficacy of exercise, diet and/or pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity: a systematic review and network meta-analysis.比较运动、饮食和/或药物干预对超重或肥胖的育龄期妇女 BMI、排卵和激素谱的疗效：系统评价和网络荟萃分析。
Hum Reprod Update. 2024 Jul 1;30(4):472-487. doi: 10.1093/humupd/dmae008.
3
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.肥胖症减肥干预措施以提高子宫内膜癌女性的生存率。
Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD012513. doi: 10.1002/14651858.CD012513.pub3.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
6
Weight loss interventions for chronic asthma.慢性哮喘的体重减轻干预措施。
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD009339. doi: 10.1002/14651858.CD009339.pub2.
7
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.肥胖治疗的长期效果、经济后果及其对健康改善影响的系统评价
Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. doi: 10.3310/hta8210.
8
Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.孕期超重或肥胖女性使用二甲双胍以改善母婴结局。
Cochrane Database Syst Rev. 2018 Jul 24;7(7):CD010564. doi: 10.1002/14651858.CD010564.pub2.
9
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.在初级保健中使用药物治疗肥胖患者的临床效果和成本效益如何？系统评价。
Health Technol Assess. 2012;16(5):iii-xiv, 1-195. doi: 10.3310/hta16050.
10
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理（2025年结石病专家共识）
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
本文引用的文献
1
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.司美格鲁肽处方治疗患者发生非动脉炎性前部缺血性视神经病变的风险。
JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296.
2
Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis.替尔泊肽、GLP-1受体激动剂及其他减肥药物在超重和肥胖症中的疗效与安全性：一项网状Meta分析
Obesity (Silver Spring). 2024 May;32(5):840-856. doi: 10.1002/oby.24002. Epub 2024 Feb 27.
3
The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.通向三重激动剂的道路：胰高血糖素样肽 1、葡萄糖依赖性胰岛素释放肽和胰高血糖素受体——更新。
Endocrinol Metab (Seoul). 2024 Feb;39(1):12-22. doi: 10.3803/EnM.2024.1942. Epub 2024 Feb 14.
4
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.每周一次司美格鲁肽 2.4mg 用于超重或肥胖的主要为东亚人群的体重管理的疗效和安全性（STEP 7）：一项双盲、多中心、随机对照试验。
Lancet Diabetes Endocrinol. 2024 Mar;12(3):184-195. doi: 10.1016/S2213-8587(23)00388-1. Epub 2024 Feb 5.
5
What is the pipeline for future medications for obesity?未来治疗肥胖症的药物研发流程是怎样的？
Int J Obes (Lond). 2025 Mar;49(3):433-451. doi: 10.1038/s41366-024-01473-y. Epub 2024 Feb 1.
6
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病血糖控制、体重和血脂水平的比较疗效：系统评价和网状Meta分析
BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410.
7
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.在肥胖成年人中继续使用替尔泊肽治疗以维持体重减轻：SURMOUNT-4 随机临床试验。
JAMA. 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.2023.24945.
8
16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2024.16. 医院中的糖尿病护理：2024 年糖尿病护理标准。
Diabetes Care. 2024 Jan 1;47(Suppl 1):S295-S306. doi: 10.2337/dc24-S016.
9
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
10
Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis.黑素皮质素-4受体激动剂Setmelanotide治疗肥胖患者的疗效与安全性：一项系统评价和荟萃分析
J Pers Med. 2023 Oct 4;13(10):1460. doi: 10.3390/jpm13101460.
Zotero 插件